Thread by @FrontRowCME

#ESMO22 final Presidential Symposium III presentation, #IPSOS, evaluating atezolizumab vs single-agent chemotherapy in pts with advanced NSCLC unsuitable for 1L standard platinum-based chemotherapy, N=453, primary EP: OS

#ESMO22 #IPSOS with a median f/u of 41 mo, atezolizumab monotherapy resulted in significantly improved OS (mOS: 10.3 vs 9.3 mo; HR-0.78; P=.028). The improved was seen across subgroups and independent of PD-L1 expression

#ESMO22 #IPSOS ORR (16.9% vs 7.9%) and DOR (14.0 vs 7.8 mo) were better with atezo, but no significant difference in PFS was found

#ESMO22 #IPSOS median treatment duration was longer with atezo and there were fewer grade 3/4 AE on the atezo arm. 13% of pts on both arms discontinued treatment due to AE. There were no new safety signals; QOL maintained

#ESMO22 #IPSOS overall for patients ineligible for 1L platinum doublet CT (the majority of pts/under-represented in clinical trials), atezolizumab monotherapy prolonged OS over single agent 3rd gen chemo

@threadreaderapp unroll